PT - JOURNAL ARTICLE AU - Damian D. Guerra AU - Daniel J. Guerra TI - Mask mandate and use efficacy for COVID-19 containment in US States AID - 10.1101/2021.05.18.21257385 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.18.21257385 4099 - http://medrxiv.org/content/early/2021/08/06/2021.05.18.21257385.short 4100 - http://medrxiv.org/content/early/2021/08/06/2021.05.18.21257385.full AB - Background COVID-19 pandemic mitigation requires evidence-based strategies. Because COVID-19 can spread via respired droplets, most US states mandated mask use in public settings. Randomized control trials have not clearly demonstrated mask efficacy against respiratory viruses, and observational studies conflict on whether mask use predicts lower infection rates. We hypothesized that statewide mask mandates and mask use were associated with lower COVID-19 case growth rates in the United States.Methods We calculated total COVID-19 case growth and mask use for the continental United States with data from the Centers for Disease Control and Prevention and Institute for Health Metrics and Evaluation. We estimated post-mask mandate case growth in non-mandate states using median issuance dates of neighboring states with mandates.Results Earlier mask mandates were not associated with lower total cases or lower maximum growth rates. Earlier mandates were weakly associated with lower minimum COVID-19 growth rates. Mask use predicted lower minimum but not lower maximum growth rates. Growth rates and total growth were comparable between US states in the first and last mask use quintiles during the Fall-Winter wave. These observations persisted for both natural logarithmic and fold growth models and when adjusting for differences in US state population density.Conclusions We did not observe association between mask mandates or use and reduced COVID-19 spread in US states. COVID-19 mitigation requires further research and use of existing efficacious strategies, most notably vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was sought because the research did not concern human subjects or identifiable patient data. All source data were publicly available from either the CDC or the IHME.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNumeric data is contained within the manuscript as supplemental Excel tables. Raw data are available from the Centers for Disease Control and Prevention (link: https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36) or the Institute for Health Metrics and Evaluation (link: https://covid19.healthdata.org/). GraphPad Prism files are available upon request. https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36 https://covid19.healthdata.org/